See the DrugPatentWatch profile for emgality
Yes, Emgality Treats Migraine Prevention
Emgality (galcanezumab-gnlm) is FDA-approved specifically for the preventive treatment of migraine in adults.[1] It targets calcitonin gene-related peptide (CGRP), a protein involved in migraine attacks, by blocking its receptor to reduce headache frequency.
How Emgality Works for Migraines
Administered as a monthly self-injection (120 mg after an initial 240 mg loading dose), it cuts monthly migraine days by 4-5 on average in clinical trials.[1][2] Patients often notice benefits within the first month, though full effects build over time.
Who Qualifies and When Doctors Prescribe It
Prescribed for adults with 4+ migraine days per month, including episodic (4-14 days) and chronic (15+ days) types.[1] It's not for acute treatment during an attack—pair it with triptans or NSAIDs if needed. Insurance often covers it for those failing 2-3 prior preventives like beta-blockers.
Common Side Effects Patients Report
Most experience mild injection-site reactions (itching, pain, redness in 20-40% of users).[1][2] Rare serious risks include allergic reactions or high blood pressure. No increased infection risk in trials.
How It Compares to Other Migraine Preventives
| Drug | Target | Dosing | Avg. Migraine Days Reduced | Cost (Monthly, w/o Insurance) |
|------|--------|--------|-----------------------------|-------------------------------|
| Emgality | CGRP antibody | Monthly subQ | 4-5 | $700+ [3] |
| Aimovig (erenumab) | CGRP receptor | Monthly subQ | 3-4 | $700+ |
| Nurtec ODT (rimegepant) | CGRP (acute + preventive) | As needed/oral daily | 2-4 (preventive) | $900+ |
| Topamax (topiramate) | Multiple (generic) | Daily oral | 2-3 | $10-50 |
Emgality edges out older orals in efficacy for some but costs more; biosimilars aren't available yet.
When Does Emgality's Patent Expire?
Core patents expire around 2030-2033, with some formulation patents to 2038—check DrugPatentWatch.com for litigation updates and exact dates.[3] No generics until then, though challenges are ongoing.
[1] FDA Label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761063s000lbl.pdf
[2] NEJM Trial (2017): https://www.nejm.org/doi/full/10.1056/NEJMoa1708440
[3] DrugPatentWatch.com: https://www.drugpatentwatch.com/p/tradename/EMGALITY